Table 3 Unstandardized effect sizes (s.e.) of the group × time × SNP interaction and their P-values

From: Therapygenetics in mindfulness-based cognitive therapy: do genes have an impact on therapy-induced change in real-life positive affective experiences?

SNP

Gene

Effect size (s.e.)

P-value

rs6265

BDNF

−0.067 (0.082)

0.415

rs11030101

BDNF

0.274 (0.089)

0.002a

rs11030102

BDNF

0.128 (0.081)

0.112

rs4680b

COMT

(a) 0.204 (0.097)

(b) −0.049 (0.110)

(c) −0.254 (0.092)

0.0360.6560.006

rs4818

COMT

−0.063 (0.085)

0.461

rs6269

COMT

−0.104 (0.086)

0.229

rs324650

CHRM2

−0.206 (0.087)

0.018

rs1824024c

CHRM2

−0.259 (0.083)

0.002a

rs6276

DRD2

−0.206 (0.079)

0.010

rs6277

DRD2

−0.156 (0.090)

0.082

rs936461

DRD4

0.426 (0.082)

0.000a

rs495491d

OPRM1

0.372 (0.081)

0.000a

rs609148e

OPRM1

0.647 (0.083)

0.000a

rs6347

SLC6A3

−0.209 (0.081)

0.009

  1. Abbreviations: BDNF, brain-derived neurotrophic factor; CHRM2, cholinergic receptor muscarinic 2; COMT, catechol-O-methyltransferase; DRD2, dopamine receptor D2; DRD4, dopamine receptor D4; OPRM1, μ1 opioid receptor; SLC6A3, dopamine transporter; SNP, single nucleotide length polymorphism.
  2. Note: the most common homozygotic genotype is the reference category (except for rs4680, of which the homozygote of the non-risk allele is the reference category); (a) tests group 1 to 0 (heterozygotic genotype to homozygote of non-risk allele), (b) tests group 2 to 0 (homozygote of risk-allele to homozygote of non-risk allele), (c) tests group 2 to 1 (homozygote of risk-allele to heterozygotic genotype).
  3. aIndicates a significant result, that is when P-values are ordered from smallest P1 to largest Pn, Pi α/(n−i+1), following Holm’s method for correcting for multiple testing.54,55
  4. brs4680 is perfectly correlated with rs4633 and highly correlated with rs4818 and rs6269.
  5. crs1824024 is highly correlated with rs2061174.
  6. drs495491 is highly correlated with rs3823010.
  7. ers609148 is perfectly correlated with rs648893.